Alterity Therapeutics Presents Positive Phase 2 Data for ATH434 in Multiple System Atrophy

Alterity Therapeutics announced positive results from its Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA) at the 2025 International Congress of Parkinson’s Disease and Movement Disorders in Honolulu, USA. The study highlights the potential of ATH434 as a first-in-class, disease-modifying therapy for MSA.

Clinical Results Show Slowing of Disease Progression

According to the company, data from the randomized, double-blind ATH434-201 trial demonstrated a meaningful slowing of disease progression and stabilization of orthostatic hypotension, a debilitating MSA symptom. New analyses further strengthened efficacy signals at the 75 mg dose, with improvements on the key UMSARS I1 clinical endpoint after 52 weeks of treatment.

Confidence in Advancing a Disease-Modifying Therapy

Dr. David Stamler, CEO of Alterity, said the findings reinforce the company’s confidence in ATH434’s therapeutic potential. “The positive data support our belief that ATH434 can significantly impact MSA treatment outcomes,” he stated. The company plans to continue advancing ATH434 toward late-stage development to address this serious neurodegenerative disorder.